Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020136281 - METHODS FOR THE PROGNOSIS OF PROSTATE CANCER

Publication Number WO/2020/136281
Publication Date 02.07.2020
International Application No. PCT/EP2019/087157
International Filing Date 30.12.2019
IPC
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/118
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
118Prognosis of disease development
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
C12Q 2600/16
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
16Primer sets for multiplex assays
C12Q 2600/172
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
172Haplotypes
Applicants
  • ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE [ES]/[ES]
Inventors
  • CARRACEDO PÉREZ, Arkaitz
  • TORRANO MOYA, Verónica
  • CORTÁZAR ORTIZ, Ana Rosa
  • ASTOBIZA PÉREZ, Ianire
  • VIERA BARDÓN, Cristina
Agents
  • ABG INTELLECTUAL PROPERTY LAW, S.L.
Priority Data
18383000.928.12.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR THE PROGNOSIS OF PROSTATE CANCER
(FR) PROCÉDÉS POUR LE PRONOSTIC DU CANCER DE LA PROSTATE
Abstract
(EN)
The present invention relates to methods useful for predicting the outcome of a patient suffering from prostate cancer or for predicting the response to therapy of a patient suffering from prostate cancer, which comprise determining, in a sample from the patient, the ratio between the average expression levels of a first gene signature and the average expression levels of a second gene signature, wherein the first gene signature is selected from the group consisting of HI1 (i.e., the CPOX, GAL3St4, ORAI2 and NIPA1 genes) and HI2 (i.e., the KHK, NOX4, PTGES3 and RRM2 genes); wherein the second gene signature is selected from the group consisting of LO1 (i.e., the ATP8B1, CDO1, CHRNA2, GLB1L3, GNE, KATNAL2, PTGIS, SLC6A14, TP53INP2, and TRIM47 genes), LO2 (i.e., the ASPA, CDO1, CYP3A5, GLB1L2, GNE, ITPKC, KCTD14, PAH, PHYHD1, SIRT1, SLC40A1, SLC7A4, and SRD5A genes) and LO3 (i.e., the ASPA, CDO1, GFPT2, GNE, ITPKC, PAH, SIRT1 and TPMT genes). These methods can be used to identify those patients who harbour an indolent/ low risk prostate cancer, or those that are at a high risk of recurrence or metastasis. The identification of these subgroups of patients may guide the selection of therapies, improving financial and health outcomes. Moreover, the expression levels of these genes can also be used for the selection of a patient to be treated for low risk, indolent, localised, advanced, recurrent or metastatic prostate cancer. Further, the invention also relates to kits and reagents to determine the expression levels of these genes.
(FR)
La présente invention concerne des procédés utiles pour prédire l'issue clinique d'un patient souffrant d'un cancer de la prostate ou pour prédire la réponse à une thérapie d'un patient souffrant d'un cancer de la prostate, consistant à déterminer, dans un échantillon provenant du patient, le rapport entre les niveaux d'expression moyen d'une première signature de génique et les niveaux d'expression moyen d'une seconde signature génique, la première signature génique étant sélectionnée dans le groupe constitué par HI1 (à savoir, les gènes CPOX, GAL3St4, ORAI2 Et NIPA1) et HI2 à savoir, les gènes KHK, NOX4, PTGES3 et RRM2); la seconde signature génique étant sélectionnée dans le groupe constitué par LO1 (à savoir, les gènes ATP8B1, CDO1, CHRNA2, GLB1L3, GNE, KATNC, PTSIG, SLC6A14, TP53INP2, et TRIM47), LO2 (à savoir les gènes ASPA, CDO1, CYP3A5, GLB1L2, GNE, ITPKC, KCTD14, HTAP, PHYHD1, SIRT1, SLC40A1, SLC7A4 et SRD5A) et LO3 (à savoir, les gènes ASPA, CDO1, GFPT2, GNE, ITPKC, HTAP, SIRT1 et TPMT). Ces procédés peuvent être utilisés pour identifier les patients présentant un cancer de la prostate indolent/à faible risque, ou ceux présentant un risque élevé de récidive ou de métastase. L’identification de ce sous-groupe de patients peut orienter la sélection des thérapies, permettre de réduire les coûts et améliorer l'issue clinique pour le patient. De plus, les niveaux d’expression de ces gènes peuvent également être utilisés pour la sélection d’un patient à traiter pour un cancer de la prostate à faible risque, indolent, localisé, avancé, récurrent ou métastasique. En outre, l’invention concerne également des kits et des réactifs servant à déterminer des niveaux d’expression de ces gènes.
Also published as
Latest bibliographic data on file with the International Bureau